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Further investigation is necessary to determine the poten-
tial clinical impact of hyperlipidemia on transplant patients. 
Specifically, the development of atherosclerotic complica-
tions, including cerebrovascular, peripheral vascular, and 
cardiovascular morbidity and mortality, must be compared in 
patients with normal versus abnormal lipid profiles. These 
findings do not suggest that hyperlipidemia in transplant 
recipients is inconsequential but rather that therapy should 
probably be based on the presence of other cardiovascular 
risk factors because when the general population of trans-
plant recipients is considered, hyperlipidemia as a single entity 
is not a significant determinant of graft or patient survival. 
Currently, we encourage reduction of cardiovascular risk fac-
tors with an exercise program, low cholesterol diet, elimination 
of smoking, weight reduction in overweight patients, and ag-
gressive blood pressure control. Pharmacotherapy is initiated in 
patients with other concomitant cardiovascular factors when 
moderate to high risk hypercholesterolemia persists despite the 
application of the aforementioned measures. 
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On the basis of observations in patients with long-
term (28-30 years) renal allograft survival, all of whom 
had evidence of systemic microchimerism, we began a 
program of combined simultaneous kidneylbone mar-
row transplantation. Between 12114192, and 10/31194,36 
kidney transplant recipients received 3-0 x 108 unmod-
ified bone marrow ceUslkg; 6 patients also received 
pancreatic islets, and 7 patients also received a pan-
1 Presented at the 14th Annual Meeting of the American Society of 
Transplant Physicians, May 15-17, 1995, Chicago, IL. 
2 Addre8s requests for reprints to Ron Shapiro, M.D., 3601 Fifth 
Ave., 4th Floor Falk Clinic, Pittsburgh, PA 15213. 
creas. The mean recipient age was 39.0±10.8 years, 
and the mean donor age was 31.8:16.1 years; the mean 
cold ischemia time was 23.0:9.1 hr. Twenty control 
patients received kidneys alone, mainly because of 
refusal by the donor family to consent to vertebral 
body recovery; 3 of these patients also received a pan-
creas. The mean recipient age was 47.9:11.7 years, 
and the mean donor age was 41.5:17.9 years; the mean 
cold ischemia time was 28.6:6.2 hr. All patients re-
ceived tacrolimus-based therapy, without radiation, 
cytoreduction, or induction antilymphocyte prepara-
tions. Blood was drawn prior to and at regular inter-
vals after transplantation for detection of chimerism 
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and for immunologic studies. With a mean follow-up of 
11.1±5.8 months, all 38 study patients are alive, and 33 
(92%) have functioning allografts with a mean serum 
creatinine of 1.9±1.2 mgtdl and a BUN of 26±9 mgtdl. 
Graft vs. host disease was not seen in any patient. The 
incidence of rejection was 72%; 11% of the patients 
required OKT3 or ATG for steroid-resistant rejection. 
The incidence of CMV was 14%, and that of delayed 
graft function was 17%. A total of 18 (90%) control 
patients are alive, and 17 (85%) have functioning al-
lografts, with a mean serum creatinine of 2.1±1.3 mgt 
dl, and a BUN of SO±13 mgtdl. The incidence of rejec-
tion was 60%, and 10% required OKT3 or ATG. CMV 
was seen in 15%, and delayed graft function in 20% 
(P=NS). In the study patients, chimerism was detected 
in the peripheral blood of 30 of 31 (97%) evaluable 
patients by either PCR or flow cytometry. In the con-
trol patients, chimerism was seen in 9 of 14 (84%) 
evaluable patients (P<.02). Decreasing donor-specific 
responsiveness was seen in 6129 (21%) evaluable study, 
and 4114 (290/0) evaluable control patients (P=NS). We 
conclude that combined kidneylbone marrow trans-
plantation is associated with acceptable patient and 
graft survival, augmentation of chimerism, and no 
change in the early events after transplantation. 
The discovery that systemic microchimerism is present in 
renal transplant recipients with stable, long-term (28-30 
years) graft survival (1) has led to the theory that chimerism 
may be required for successful long-term engraftment (2-4). 
These observations resulted in trials of donor bone marrow 
infusion at the time of renal (or other solid organ) transplan-
tation, with the goal of augmenting levels of chimerism and 
improving long-term patient and graft survival (5-7). An 
early report of the first ten kidney recipients showed reason-
able short-term patient and graft survival with routine aug-
mentation of chimerism and no evidence of graft vs. host 
disease (GVHD) (8). The incidence of rejection, delayed graft 
function, and cytomegalovirus was not different from that 
observed in control patients who did not receive bone mar-
row. The present report discusses the outcome in the first 36 
patients undergoing combined kidneylbone marrow trans-
plantation. 
MATERIALS AND METHODS 
Between December 17, 1992, and October 31. 1994, 36 patients 
underwent combined, simultaneous kidneylbone marrow transplan-
tation. Six patients also received islets. and 7 also received a pan-
creas, in each case from the same donor. The mean recipient age was 
39.0::10.8 years (range 18.7-63.4). Two (6%) patients were under-
going retransplantation, and one (3%) had a panel-reactive antibody 
level (PRA) greater than 40%. One (3%1 patient received a living 
related donor kidney and bone marrow from a 1 haplotype-matched 
brother; the remainder received kidneys and bone marrow from 
cadaveric donors. whose mean age was 31.8:: 16.1 years (range 7.0-
(iOl. The mean number of HLA matches and mismatches was 2.3::': 1.3 
and 3,4::,: 1.5. respectively, and the mean cold ischemia time was 
23.0::':9.1 hr (range 7.5-44.2). 
Twenty control patients underwent kidney transplantation alone: 
the most common reason for the lack of availability of donor bone 
marrow was family refusal to give consent for vertebral body recov-
ery. Three patients also received a pancreas. All patients were un-
dergoing their first cadaveric transplantation, and one \5%) had a 
PRA over 40%. These patients and their donors were somewhat 
older: the mean recipient age was 47.9:: 11.7 years (range 29.7-66.3: 
P<.01, compared with the kidneylbone marrow recipients). The 
mean donor age was 41.5±17.9 years (range 5.0-67.0; P<.05, com-
pared with the kidneyibone marrow group). The mean numbers of 
HLA matches and mismatches were 2.6::1.3 and 3.4:!:1.4 (P=ns 
compared with the kidneylbone marrow group), and the mean cold 
ischemia time was 28.6±6.2 hrs (range 17.8-37.9, P<.02 compared 
with the kidneylbone marrow recipients). Some of these differences 
were related to the large number of diabetes undergoing islet or 
pancreas transplantation in the bone marrow group. When kidney-
only recipients were considered, the bone marrow and control pa-
tients were not statistically different in terms of donor or recipient 
age, or cold ischemia time. 
Immunosuppression was with tacrolimus and steroids, as previ-
ously described (9). Induction antilymphocyte therapy, cytoreduc-
tion, or radiation therapy was not given to any patient. 
Bone marrow isolation. Bone marrow, in all but one case, was 
recovered from the donor vertebral bodies, the method for which has 
been described elsewhere (5). Briefly, the vertebral bodies were bro-
ken up into small cancellous bone chips and placed in a processing 
medium (8) for 30-60 min, during which time the bone marrow cells 
were passively released. The cell suspension was then fIltered and 
centrifuged at 300 xg for 11 min, and the pellet was placed in a 
suspension medium (8). The cell number and viability were deter-
mined by trypan blue dye exclusion. The cells were diluted with the 
suspension medium to a concentration of 2X107 cells/ml, and then 
refrigerated at 4°C until the recipient was ready. At that point, the 
cell suspension was centrifuged and resuspended in 200 ml of the 
suspension medium, and given intravenously over a period of 20-30 
min. 
In the living related case, donor bone marrow was aspirated from 
the iliac crest after completion of the donor nephrectomy and pro-
cessed in a standard manner (10). In all cases, 3-5 X 108 unmodified 
donor bone marrow cells/kg were given intravenously at the conclu-
sion of the kidney transplant procedure. 
Chimerism and in vitro immune testing studies. Just prior to and 
at regular intervals following transplantation, blood was drawn for 
detection of chimerism by fluorescent activated cell sorter analysis 
(FACS), and polymerase chain reaction (PCR). Serial in vitro im-
mune monitoring was also performed using mixed lymphocyte reac-
tions and assays to determine reactivity to recall antigens and mi-
togens. 
FACS. In all immunostaining procedures, mouse-antihuman 
monoclonal antibodies (mAbl directed against the polymorphic 
epitopes ofHLA class I were used to distinguish donor from recipient 
HLA alleles. These primary mAb were labeled with either fluores-
cein isothiocyanate (FITC) or phycoerythrin (PEl-conjugated goat· 
antimouse secondary antibodies. The specificity and the optimal 
dilution of each were determined by staining donor spleen cells and 
the recipient's pretransplant peripheral blood mononuclear cells 
(PBMC1. To delineate leukocyte lineages, PE or FITC-conjugated 
mouse-antihuman mAbs directed against different cell surface re-
ceptors were used. Isotype-matched irrelevant mAbs were used as 
negative controls. FACS was feasible in 25 of the 31 study patients 
and 12 of the 18 control cases. Frequency of cells <0.5% was consid· 
ered below the reliable detection threshold. 
PCR. A search for chimerism was feasible in 24 of the 31 study 
cases and 11 of 18 control patients using oligonucleotides of either 
the sex determining region of the V-chromosome (SRYl or the appro-
priate mismatched HLA alleles as primers. The DNA was amplified 
and resolved by electrophoresis on an agarose gel. Mter Southern 
blotting, the membrane was hybridized with a specific radiolabeled 
probe. exposed to a film, and developed. 
In·vitro immune testing. The in·vitro immune status of the recip· 
ients before and after transplantation was determined by the reo 
sponse of recipient's PBMC to ConA and PHA mitogens and recall 
antigen, and mixed lymphocyte reaction (MLR). In these unidirec· 
tional human MLR cultures. gamma-irradiated donor splenocytes. 
and third-party PBMC were used as stimulators (105 cells/weill. The 
cells were cultured at 37°C for 6 days in 5% CO2 in air; for the final 
s 
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20 hr [3Hl thymidine [1/J.cil was added to each well and its degree of 
incorporation was determined by liquid scintillation counting. 
Pancreatic islets were infused into a branch of the portal vein 
after completion of the renal transplant procedure. Islet preparation 
was according to previously described techniques (11, 12). Similarly, 
the pancreas transplant was performed either immediately before or 
after the renal transplant procedure, using standard techniques (13). 
Statistical analysis. The standard two-sample t test was used to 
test differences in means, while differences in rates and proportions 
were tested using Pearson's chi-square test of association. A P-value 
less than 0.05 was considered statistically significant. 
RESULTS 
The mean follow-up was 11.1:!:5.8 months (Table 1). All 
kidneytbone marrow recipients were alive, and 33 (92%) had 
functioning allografts. Two patients lost their allografts 16 
months after transplantation, one to noncompliance and the 
other to rejection. One additional patient lost his allograft 
12.5 months after transplantation to a combination of poly-
oma (B-K) virus infection and rejection. The mean serum 
creatinine and BUN were 1.9:!:1.2 mg/dl and 26:!::9 mg/dl. 
Rejection, which was documented histologically in all cases, 
was seen in 26 (72%) patients-however, only 4 (11%) pa-
tients required antilymphocyte therapy. 
The mean tacrolimus dosage was 10.0:!:6.0 mg/d, and the 
level (whole blood IMX) was 10.4:!:4.4 ng/ml; 13 (39%) pa-
tients were ofT steroids, and the mean prednisone dosage for 
the patients still on steroids was 6.1:!:3.3 mg/d. 
In the control group, 18 (90%) patients were alive; one 
patient died of sepsis 2 months after transplantation, having 
lost his kidney for technical reasons 1 month earlier. Another 
patient died of suspected hyperkalemia 5 months after trans-
plantation, having at that time lost her allograft to rejection. 
An additional patient lost her allograft two weeks after 
transplantation to vascular rejection; thus 17 (85%) of the 
control patients have functioning allografts. The mean serum 
creatinine and BUN were 2.1:!:1.3 mg/dl and 30:!:13 mg/dl. 
Rejection was seen in 12 (60%) patients; 2 (10%) patients 
required antilymphocyte therapy. 
The mean tacrolimus dosage was 8.0:!:5.0 mg/d, and the 
level was 8.8:!::4.3 ng/ml: 8 (47%) of the patients were off 
TABLE 1. Outcome after kidney transplantation with and without 
bone marrow augmentation 
Follow'lIp 
Patient survival 
Graft survival 
Serum creatinine (mg/dll 
BUN (mg/dll 
RejectIOn 
OKT3 or ATG 
Tacrolimus dose (mg/dl) 
Tacrolimus level (nglml) 
Off sterOIds 
Cytomegalovi rus 
Delayed graft function 
Graft vs. host disease 
ChimerIsm 
Decreasing donor-
specific responsiveness 
Kidney/bone marrow 
(n=36) Control (n = 20) 
11.1 ::': 5.8 Months 
100% 90% 
92% 85% 
1.9 ::': 1.2 2.1 ::': 1.:3 
26::': 9 :30:!: 13 
26 (72,}) 12 (607<) 
4 (U'Jr) 2(10%) 
10.0::': 6.0 8.0::': 5.0 
10.4 :!: -1.4 R.8::': 4.3 
13 (39'7c) 8 (47'7r) 
5 (14';,,) :3 (I5'!,) 
6 (17<;1 ) 4 (207<) 
o Wo/c) o (Qo/c) 
30/31 (97,})" 9/14 (64'7c) 
6/29 (21,}) 4114 (29'1-) 
" P<.02. all other comparisons. m~kpK 
steroids, and the mean prednisone dosage for those patients 
still on steroids was 6.1:!:2.5 mg/d. 
Cytomegalovirus was diagnosed in 5 (14%) kidneytbone 
marrow and 3 (15%) control patients, all of whom received 
and responded to intravenous gancyclovir. Delayed graft 
function was observed in 6 (17%) kidneylbone marrow and 4 
(20%) control patients (P=ns compared with kidneytbone 
marrow patients for all the above survival, function, dosage, 
and complication data). 
Graft-versus-host disease was not observed in any patient 
(14). 
Thirty-one of the 33 kidneylbone marrow patients with 
functioning grafts were evaluable for chimerism by flow cy-
tometry and/or PCR. The others could not be evaluated be-
cause of a perfect DR match or a lack of donor/recipient sex 
disparity. As expected, chimerism was not detectable in the 
pretransplant blood specimen of any patient. At most recent 
follow-up after transplantation, 30 (97%) kidneytbone mar-
row patients had evidence of persistent peripheral blood chi-
merism by one or more modality (Fig. 1 and 2). Of 14 control 
patients who were evaluable for chimerism, 9 (64%) were 
chimeric (P<.02). In general, the level of chimerism appeared 
to be higher in the bone marrow-augmented group than in 
the control patients. 
Serial mixed lymphocyte reaction (MLR) evaluation was 
performed to look for decreasing donor-specific responsive-
ness. This was seen in 6 of 29 (21%) evaluable kidneytbone 
marrow recipients and 4 of 14 (29%) evaluable control pa-
tients (P=NS [Table 1]). There was evidence of a correlation 
between an increasing responsiveness and rejection in two 
patients who went on to lose their allografts to rejection. One 
of the cases was the patient who lost his kidney to noncom-
pliance, who had evidence of donor-specific hyporesponsive-
ness prior to discontinuing his immunosuppression. 
DISCUSSION 
Bone marrow augmentation is in some sense a conceptual 
descendant of pretransplant donor-specific blood transfu-
sions, although many of the details are obviously different 
(15). Common to both ideas is the goal of improving long-term 
graft survival by immunomodulation. Our data suggest that 
bone marrow augmentation is associated with acceptable 
patient (100%) and graft (92%) survival, no graft-versus-host 
disease, and a similar incidence of routinely observed post-
transplant complications. when compared with the control 
group. Chimerism was observed more frequently (97%) and 
at a higher level than in the control group (64%), Thus bone 
marrow augmentation was not harmful and was associated 
with an increase in chimerism. It should be noted that this 
was not a randomized trial and that the control group was 
older, both in terms of recipient and donor age, and had a 
longer cold ischemia time. It took nearly two years to accrue 
36 patients, and over one-third had the allocation advantage 
of receiving islets or a whole pancreas. The average annual 
number of kidney transplantations during this period was 
200-thus a very small percentage of patients was able to be 
entered into this trial. To perform a randomized trial in this 
circumstance would not have allowed for any sort of mean-
ingful case accrual. The disparity in age and cold ischemia 
time is a reflection of the disproportionate number of diabet-
ics receiving islets or a whole pancreas: these patients tend to 
be younger than the average renal transplant patient. and 
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FIGURE 1. Flow cytometric analysis of a kidney and bone marrow 
recipient 260 d posttransplantation. Cells stained with donor (HLA-
A3) or recipient (HLA-B8) specific mAb were acquired using wide 
gates on a light scatter profile (A). (E) Recipient cells (91.5%) (F) 
Donor cells (2.6%). Unstained fB) and cells stained with isotype-
matched irrelevant mAb (D) were used as controls. Axes: (C) 
CD45-X, CD14-Y; (0) IgG 2b-X; (E) HLA-B8-X; (F) HLA-
A3-X. 
the ischemia time tends to be shorter as well. When we 
compared the 23 kidney-only bone marrow patients with the 
17 kidney-only control patients, the mean donor and recipi-
ent age and cold ischemia time were not statistically differ-
ent. 
The long-term questions in the kidneylbone marrow pa-
tients await more follow-up. Improvement in long-term graft 
survival. persistence of chimerism. and an increase in donor-
specific hyporesponsiveness are all issues that will need to be 
studied over the next several years to establish the utility of 
bone marrow augmentation. Questions about the optimal 
way to perform bone marrow augmentation are still being 
addressed. Our regimen of a single perioperative dose of bone 
marrow and no induction antilymphocyte therapy, cytore-
duction. or radiation represents the most straightforward 
approach. Other approaches have included delayed admin-
istration with induction antilymphocyte therapy (16-20). 
pretransplant radiation therapy and modification of the bone 
marrow 121-23). and administration of more than one dose of 
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FIGURE 2. Detection of donor DNA by PCR in the peripheral blood of 
two female recipients of kidney and bone marrow from male donors 
for up to 484 (II) and 261 (III) days posttransplantation. (I) Titration 
curve to determine the sensitivity of the detection of the SRY-region 
of the V-chromosome; log dilutions from 100 to 0.001 ng in lanes A to 
F respectively. (II) Evidence for the presence of donor DNA on POD 
252 (A), 266 (B), 428 (C), and 484 (D). (III) Donor DNA was also 
detected in another BM-augmented kidney + islet recipient on D15 
(A), 163 (B), and 261 (C) posttransplantation. 
donor bone marrow (Tzakis A, Miller J, Ricordi C., personal 
communication). The long-term assessment of these different 
approaches will take years, and it thus may not be straight-
forward to establish which regimen will be the most useful. 
What our study has demonstrated is that short-term patient 
and graft survival are acceptable. that there is augmentation 
of the incidence and level of chimerism, and that the proce-
dure is safe, with no evidence of graft-versus-host disease. 
These findings confirm our earlier reports in a larger number 
of patients. Accrual of cases in our program is continuing. 
Routine vertebral body recovery in other centers may allow 
for more widespread application of bone marrow augmenta-
tion and may facilitate sharing of organs and bone marrow 
between different centers. 
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